Reduction of dopamine D 2/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys

R-ketamine appears to be a potent, long-lasting and safer antidepressant, relative to esketamine (S-ketamine), since it might be free of psychotomimetic side effects. Using [ C]raclopride and positron emission tomography (PET), we investigated whether esketamine and R-ketamine can affect dopamine D...

Full description

Saved in:
Bibliographic Details
Published in:European archives of psychiatry and clinical neuroscience 2017-03, Vol.267 (2), p.173
Main Authors: Hashimoto, Kenji, Kakiuchi, Takeharu, Ohba, Hiroyuki, Nishiyama, Shingo, Tsukada, Hideo
Format: Article
Language:English
Subjects:
Animals
Antidepressive Agents - administration & dosage
Antidepressive Agents - pharmacology
Ketamine - administration & dosage
Ketamine - pharmacology
Macaca mulatta
Male
Neostriatum - diagnostic imaging
Neostriatum - drug effects
Positron-Emission Tomography - methods
Receptors, Dopamine D2 - metabolism
Receptors, Dopamine D3 - metabolism
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:R-ketamine appears to be a potent, long-lasting and safer antidepressant, relative to esketamine (S-ketamine), since it might be free of psychotomimetic side effects. Using [ C]raclopride and positron emission tomography (PET), we investigated whether esketamine and R-ketamine can affect dopamine D receptor binding in the conscious monkey brain. A single infusion of esketamine (0.5 mg/kg), but not R-ketamine (0.5 mg/kg), caused a reduction of binding availability of dopamine D receptor in the monkey striatum. This study suggests that unlike to R-ketamine, esketamine can cause dopamine release in the striatum, and that its release might be associated with psychotomimetic effects of esketamine.
ISSN:1433-8491
DOI:10.1007/s00406-016-0692-7